VENICE, Fla., Dec. 7, 2010 (GLOBE NEWSWIRE) -- SinoFresh® HealthCare, Inc., (Pink Sheets:SFSH) is pleased to announce that it has acquired SRS International, Inc.(), a leading consulting and regulatory company specializing in research and development, compliance and other regulatory matters. The acquisition of SRS International now forms the cornerstone of the Research and Development division of SinoFresh HealthCare, Inc.
SRS International Corporation as a wholly owned operating subsidiary of SinoFresh HealthCare, Inc. will interface both domestically and globally to efficiently introduce and support SinoFresh products entering the marketplace. Extensive experience in Asia as well as the Western world makes SRS International Corporation the perfect acquisition to support the development and introduction of SinoFresh HealthCare, Inc. product lines in both the national and international markets.
John Todhunter, Principal of SRS International, has a distinguished record of representing companies before the Food and Drug Administration and the Environmental Protection Agency, as well as designing and conducting clinical studies. Todhunter is a former Presidential Appointee, having been appointed to the EPA by President Ronald Reagan.
SinoFresh CEO David R. Olund comments, "The acquisition of SRS International and the addition of John Todhunter to our team are significant events and signal a vote of confidence in the future of SinoFresh HealthCare, Inc., by SRS International, a leading company in the pharmaceutical research and development and clinical studies field. The DSRS International team immediately brings us regulatory and product development expertise at a level of competence and experience that could not easily be duplicated by an emerging growth-oriented company. Overall, we are truly fortunate to have a world-class team and John Todhunter forming our R&D division."
SinoFresh HealthCare, Inc. is a publicly traded company (Pink Sheets:SFSH) based in Venice, Florida, that manufactures and distributes nasal, oral and topical antiseptic germ-killing products. SinoFresh products are marketed and distributed globally through a network of strategic wholesale and retail partners. SinoFresh HealthCare, Inc's, premier product, SinoFresh Antiseptic Homeopathic Nasal spray, has in laboratory tests shown effective antiseptic capability against a variety of pathogens such as MRSA, E-Coli, H1N1 and a broad range of other viruses, molds, fungi and bacteria.
For more information please contact our Investor Relations department at 941.375.8174 option 8
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Our forward-looking statements express our current expectations or forecasts of possible future results or events, including projections of future performance, statements of management's plans and objectives, future contracts, and forecasts of trends and other matters. Forward-looking statements speak only as of the date of this filing, and we undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur. You can identify these statements by the fact that they do not relate strictly to historic or current facts and often use words such as "anticipate", "estimate", "expect", "believe", "will likely result", "outlook", "project" and other words and expressions of similar meaning. No assurance can be given that the results in any forward-looking statements will be achieved and actual results could be affected by one or more factors, which could cause them to differ materially. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act.
CONTACT: Sinofresh Healthcare Inc. Investor Relations 941.375.8174 option 8